Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 731.05
Open 735.75
Day range 704.80 737.05
52-week range 410.10 839.25
Off day high −3.81%
Off 52-week high −15.52%
Volume 18.34K
Avg. volume (3M) 13.94K
Market cap 108.55B
EPS (TTM) 19.05
Forward P/E 20.77
P/E ratio (TTM) 37.22
Dividend yield 0.14% (1.00)
Beta (5Y) 0.56
Shares outstanding 153.10M
Short interest —
Earnings date Aug 22, 2025
Analyst target 863.33
Profit margin 6.48%
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets…
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Employees 7,337
Headquarters Delhi, India
Strong buy 3 analysts
0 3 0 0 0 12-month price target 863.33 +21.77%
Low 850.00 Current 709.00 High 880.00
Wall Street analyst consensus. Not a recommendation.
Earnings
Next report: Fri, Aug 22, 2025
Net margin 8.6% (Q2 '26) Prices may be delayed up to 15 min. Not investment advice.
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use .